We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Powered by Human Immunity

Based in Cambridge, UK, we are making better medicines by continually improving our antibody discovery technologies

Learn more

Unique antibodies, unique solutions

Our unique technologies drive the rapid development of effective, human antibody-based drugs across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.

View our pipeline

World-leading partners

  • Bill & Melinda Gates Foundation
  • Heptares Therapeutics
  • Novo Nordisk
  • LifeArc
View our partnerships

Come and make a difference with us

Join us in developing tomorrow's medicines: we're driven by passion for better healthcare and by compassion to make a difference. Join our experienced and successful team and help us to realise our aims.

View our vacancies

Our latest news and events

6 Dec 2019

Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition

Cambridge, UK; December 6, 2019: Kymab, a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody-based th...

Read article

13 Nov 2019

Kymab to Present Update on Lead Immunocytokine Program KY1043 at Two European Scientific Meetings in November 2019

KY1043, a bifunctional, PD-L1-based, IL-2Rα (CD25)-directed immunocytokine, binds and blocks the activity of PD-L1 on PD-1 and pre...

Read article

8 Nov 2019

Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting

KY1043, a bifunctional, PD-L1-based, IL-2Rα (CD25)-directed immunocytokine stimulates potent anti-tumor responses in vivo leading ...

Read article

3 Oct 2019

Kymab Announces Presentation on KY1049 at the European Congress on Thrombosis and Haemostasis

Oral presentation to outline the development and preclinical evaluation of KY1049, the first fully human Factor VIII-mimetic bispecific ...

Read article

27 Sep 2019

Kymab outlines positive new findings for its KY1044 Anti-ICOS program at the CICON 2019 Annual Meeting

KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor regression Expanding data set continues to ...

Read article

2 Sep 2019

Kymab has defeated an opposition by Regeneron against the grant of an Australian patent covering transgenic mouse platforms for antibody discovery on all grounds

The Australian Patent Office additionally disallowed Regeneron's Murphy patent application on Reverse Chimeric antibodies due to lack of...

Read article